Section 6: Education and Research

6ER-018

USE OF ELTROMBOPAG IN ROUTINE CLINICAL PRACTICE

6ER-014

ANALYSIS OF THE EVOLUTION OF INTERLEUKIN-6 IN COVID-19 PATIENTS AFTER BEING TREATED WITH DEXAMETHASONE

6ER-013

ANALYSIS OF PATIENTS’ MORTALITY IN SARS-COV-2 INFECTION DURING THE FIRST MONTH OF HOSPITAL ADMISSION

6ER-012

EFFECTIVENESS OF IL-23 INHIBITORS IN PATIENTS WITH MODERATE–SEVERE CHRONIC PLAQUE PSORIASIS

6ER-011

COTRIMOXAZOL: HOW FOLATE SUPPLEMENTATION COULD AFFECT TREATMENT EFFICACY

6ER-008

DEVELOPMENT OF A RISK-SHARING MODEL BASED ON THE CLINICAL PERFORMANCE OF ONASEMNOGENE ABEPARVOVEC (ZOLGENSMA)

6ER-007

REAL-WORLD EFFECTIVENESS OF GENE THERAPY ONASEMNOGENE ABEPARVOVEC (ZOLGENSMA) FOR SPINAL MUSCULAR ATROPHY: A REVIEW

6ER-006

PARACETAMOL VERSUS IBUPROFEN FOR TREATMENT OF PERSISTENT DUCTUS ARTERIOSUS CLOSURE IN PRETERM INFANTS: IBUPAR-TRIAL

6ER-002

Applying reflective Multicriteria Decision Analysis to understand the value of therapeutic alternatives in the management of anaemia in gynaecologic surgery

6ER-001

CAN PHARMACISTS IMPROVE THEIR PATIENT COMMUNICATION BY READING FICTION?

6ER-037

DRUG - DRUG INTERACTIONS WITH QT PROLONGING DRUGS IN PATIENTS ADMITTED TO A CARDIOVASCULAR DEPARTMENT: A RETROSPECTIVE ANALYSIS

6ER-036

DEPRESCRIBING TOOLS FOR THE ELDERLY: A SYSTEMATIC REVIEW

6ER-035

AN EVALUATION OF HEALTH PROMOTION AND DISEASE PREVENTION KNOWLEDGE IN PATIENTS ATTENDING A HOSPITAL OUTPATIENT PHARMACY

6ER-034

MEDICATION DEPRESCRIBING AND FOLLOW-UP: A SURVEY AMONG SUBACUTE MULTIMORBID PATIENTS IN A MULTIDISCIPLINARY OUTPATIENT CLINIC

6ER-033

PHARMACIST LED DEPRESCRIBING AND FOLLOW-UP IN A SUBACUTE MULTIDISCIPLINARY OUTPATIENT CLINIC: A PILOT RANDOMISED CONTROLLED TRIAL

Pages